Venture financing holds steady for device makers
Medtech VCs have plenty of cash, which is just as well because the IPO window is shut and locked.
Private equity gets serious about drug development
Venture capital has the brains, private equity has the books – can they make lots of money?
The other shoe finally drops for device dealmaking
A combination of Covid and market gloom results in the fewest acquisitions closing for over 20 years.
Few biopharma risers stand out at the half year
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
The retrenchment begins for venture funding
The gloomy climate for biotech is now taking its toll on private companies too.
Medtech research spending set to slow in 2022
And some diagnostics groups are forecast to actually cut R&D outlay this year as the pandemic eases.
Biotech smells the coffee
A couple of small M&A deals this week shows more developers capitulating to the new reality.
